ID: ALA3398484

Max Phase: Preclinical

Molecular Formula: C15H25ClN6O2

Molecular Weight: 320.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCOc1nc(N)c2[nH]c(=O)n(CC3CCNCC3)c2n1.Cl

Standard InChI:  InChI=1S/C15H24N6O2.ClH/c1-2-3-8-23-14-19-12(16)11-13(20-14)21(15(22)18-11)9-10-4-6-17-7-5-10;/h10,17H,2-9H2,1H3,(H,18,22)(H2,16,19,20);1H

Standard InChI Key:  PANCBMFBNCXZAT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 320.40

Molecular Weight (Monoisotopic): 320.1961

AlogP: 0.88

#Rotatable Bonds: 6

Polar Surface Area: 110.85

Molecular Species: BASE

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.34

CX Basic pKa: 10.35

CX LogP: 1.47

CX LogD: -1.20

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.68

Np Likeness Score: -0.57

References

1. Bazin HG, Li Y, Khalaf JK, Mwakwari S, Livesay MT, Evans JT, Johnson DA..  (2015)  Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.,  25  (6): [PMID:25698055] [10.1016/j.bmcl.2015.01.037]

2. Bazin HG, Bess LS, Livesay MT, Li Y, Cybulski V, Miller SM, Johnson DA, Evans JT..  (2020)  Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.,  30  (6): [PMID:32001135] [10.1016/j.bmcl.2020.126984]

Source

Source(1):

• Scientific Literature